Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD
NCT07773883Phase 3Enrolling by invitation
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Aug 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of solriamfetol in attention deficit hyperactivity disorder (ADHD), sponsored by Axsome Therapeutics, Inc. Primary endpoint: Treatment-Emergent Adverse Events up to 52 weeks. Started Aug 2026; status: enrolling by invitation.
02
Drugs
solriamfetol
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT07773883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07773883.